Karyopharm Therapeutics Inc (NASDAQ:KPTI) has earned an average rating of "Buy" from the thirteen research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $33.00.
Several analysts have weighed in on the company. Barclays reissued a "buy" rating and set a $31.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, June 23rd. Morgan Stanley assumed coverage on Karyopharm Therapeutics in a report on Wednesday, July 1st. They set an "overweight" rating and a $34.00 price objective for the company. SVB Leerink dropped their price objective on Karyopharm Therapeutics from $31.00 to $30.00 and set an "outperform" rating for the company in a report on Tuesday, August 4th. Royal Bank of Canada upped their price target on Karyopharm Therapeutics from $28.00 to $30.00 and gave the company an "outperform" rating in a research note on Tuesday, June 23rd. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. upped their price target on Karyopharm Therapeutics from $31.00 to $37.00 and gave the company an "overweight" rating in a research note on Tuesday, June 23rd.
In related news, EVP Christopher Brett Primiano sold 10,054 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $14.98, for a total transaction of $150,608.92. Following the completion of the sale, the executive vice president now directly owns 14,703 shares of the company's stock, valued at approximately $220,250.94. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider John Demaree bought 7,500 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were acquired at an average cost of $14.54 per share, with a total value of $109,050.00. Following the completion of the purchase, the insider now owns 7,500 shares in the company, valued at approximately $109,050. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 41,531 shares of company stock valued at $754,014. 11.63% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. AXA acquired a new position in Karyopharm Therapeutics during the 1st quarter worth approximately $1,024,000. Deutsche Bank AG boosted its position in Karyopharm Therapeutics by 46.1% during the 1st quarter. Deutsche Bank AG now owns 150,825 shares of the company's stock worth $2,897,000 after acquiring an additional 47,595 shares during the last quarter. State of Wisconsin Investment Board boosted its position in Karyopharm Therapeutics by 7.5% during the 2nd quarter. State of Wisconsin Investment Board now owns 98,800 shares of the company's stock worth $1,871,000 after acquiring an additional 6,900 shares during the last quarter. First Trust Advisors LP acquired a new position in Karyopharm Therapeutics during the 2nd quarter worth approximately $1,769,000. Finally, TD Asset Management Inc. boosted its position in Karyopharm Therapeutics by 73.6% during the 2nd quarter. TD Asset Management Inc. now owns 53,787 shares of the company's stock worth $1,019,000 after acquiring an additional 22,795 shares during the last quarter. 95.90% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ KPTI opened at $16.08 on Tuesday. The firm's 50-day simple moving average is $15.10 and its 200 day simple moving average is $18.49. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -5.66 and a beta of 1.18. The company has a quick ratio of 6.25, a current ratio of 6.29 and a debt-to-equity ratio of 0.88. Karyopharm Therapeutics has a 12-month low of $8.91 and a 12-month high of $29.61.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by ($0.06). The firm had revenue of $33.51 million for the quarter, compared to the consensus estimate of $28.03 million. Karyopharm Therapeutics had a negative return on equity of 186.76% and a negative net margin of 228.44%. On average, equities analysts expect that Karyopharm Therapeutics will post -2.63 earnings per share for the current year.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
Recommended Story: Straddles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Energy Stocks to Buy On This Historical Dip
It may seem hard to believe, but the current chaos in the energy sector, and oil stocks, in particular, will pass. The novel coronavirus that has birthed a global pandemic is being compared to the Spanish Flu of 1918.
Of course, when you have once in a century event, it’s difficult to look back in history and make an apples-to-apples comparison to our current situation. This isn’t to minimize our current situation. It’s simply to say that the market is forward-looking, but it’s also emotional. And it also hates uncertainty.
In a typical economic downturn, demand decreases, and investors are advised to “buy the dip.” But in the current environment, demand has been destroyed. Millions of Americans are being asked, and in some cases ordered, to stay home. And this simply means that oil demand is down. And investors are looking at prices that are, in some cases, at all-time lows.
The trading app Robinhood is frequented by millennial investors. And according to the latest information, many investors are trying to buy the dip on old guard oil stocks. That may be a mistake.
But the energy sector is about more than just oil stocks. There are several companies that are holding their own in the current environment. And that means when the economy opens up, these companies will be well-positioned for further growth.
Currently, the volatility and uncertainty surrounding energy stocks make them a poor choice for growth investors. However, many of these companies in this presentation offer a secure dividend that, along with the potential for capital appreciation, can make them a solid play for income investors.
View the "7 Energy Stocks to Buy On This Historical Dip".